<DOC>
	<DOCNO>NCT00569790</DOCNO>
	<brief_summary>The purpose study determine whether irinotecan , S-1 , bevacizumab safe treatment unresectable recurrent colorectal cancer</brief_summary>
	<brief_title>Phase II Trial Combination Therapy With Irinotecan , S-1 , Bevacizumab ( IRIS/Bev ) Patients With Unresectable Recurrent Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Histologically confirm colorectal carcinoma inoperable , locally advanced , metastatic disease , amenable curative therapy 2 . Measurable disease nonmeasurable assessable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) 3 . Patients previous treatment ( radiotherapy chemotherapy ) . Patients receive postoperative adjuvant chemotherapy eligible relapse diagnose 180 day end treatment . 4 . Age ≥20 year 5 . Life expectancy least 3 month 6 . ECOG PS 0 1 7 . Adequate function major organ define : 1 . Hemoglobin ≥9.0g/dL 2 . White blood cell count ≥3,500/mm3 3 . Neutrophil count ≥1,500/mm3 4 . Platelet count ≥100,000/mm3 5 . Total bilirubin ≤1.5 mg/dL 6 . AST ALT ≤100 U/L ( &lt; 200 U/L patient liver metastasis ) 7 . Serum creatinine ≤1.2 mg/dL 8 . Creatinine clearance estimate CockcroftGault method &gt; 50 mL/min ( reduce initial dosage one step ≥50 &lt; 80 mL/min ) 8 . Able take capsule orally . 9 . No electrocardiographic abnormality within 28 day enrollment would clinically preclude execution study , judge investigator . 10 . Voluntary write informed consent . 1 . Serious drug hypersensitivity history drug allergy 2 . Active double cancer 3 . Active infection ( e.g. , patient pyrexia 38℃ high ) 4 . History gastrointestinal perforation , intestinal tract paralysis , ileus within 1 year . 5 . Uncontrolled hypertension 6 . Serious complication ( e.g. , pulmonary fibrosis , interstitial pneumonitis , heart failure , renal failure , hepatic failure , poorly control diabetes ) 7 . Moderate severe ascites pleural effusion require treatment 8 . Watery diarrhea 9 . Treatment flucytosine atazanavir sulfate 10 . Metastasis CNS 11 . Pregnant woman , possibly pregnant woman , woman wish become pregnant , nursing mother . Men currently attempt conceive child . 12 . Severe mental disorder 13 . Continuous treatment steroid 14 . Urine dipstick proteinuria &lt; 2+ 15 . Patient past history thrombosis , cerebral infarction , myocardial infarction , pulmonary embolism 16 . Major surgical procedure , open biopsy , clinically significant traumatic injury within 4 week 17 . Longterm daily treatment aspirin ( &gt; 325 mg/day ) 18 . History evidence inherit bleed diathesis coagulopathy risk bleed 19 . Judged ineligible participation study investigator safety reason .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>S-1</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>